• Glaukos launched Epioxa commercially in March 2026 as the first FDA-approved epithelium-on treatment for keratoconus.
• Revenue grew more than 30% in 2025, with a 10-year compound annual growth rate exceeding 20%.
• iDose TR received FDA approval for repeat administration in January 2026, supporting reuse of the long-duration glaucoma therapy.
• A new Phase 3 analysis showed iDose TR was noninferior to topical timolol at three years.
• The iDose pipeline includes TRIO in Phase 3b, with patient enrollment completed; TREX is advancing through a Phase 2b/3 program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.